Valo Therapeutics Acquires PeptiCHIP Technology Enabling Rapid Identification of Tumor Antigens for the Development of Personalized Immunotherapies
Helsinki, Finland, 26 July 2022: Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, announces the exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s innovative PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. This is a strategically important addition for the company as it will enable the rapid identification of tumour antigens for the development of new cancer immunotherapies using Valo’s existing technologies and opens the possibility for a tumor specific personalized approach in the future. In addition, due to the advantages PeptiCHIP offers in comparison to existing antigen identification approaches, ValoTx expects to be able to commercialise the technology through creating a revenue-generating business unit.